Meyer Alexa R, Allaf Mohamad E, Rowe Steven P, Gorin Michael A
The James Buchanan Brady Urological Institute and Department of Urology.
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Curr Opin Urol. 2018 Mar;28(2):159-165. doi: 10.1097/MOU.0000000000000479.
To explore the role of molecular imaging in the characterization of renal masses.
Incidentally detected renal masses exhibit variable malignant potential related to their underlying histology. Patients presenting with a renal mass should undergo individual risk stratification including characterization of their tumor histology. At the present time, anatomical imaging techniques are unable to reliably distinguish between the various renal tumor subtypes. Although renal mass biopsy is helpful in this regard, there are limitations of this procedure. Molecular imaging offers a noninvasive means of determining the histology of renal tumors. Imaging tests that have shown particular promise for this application include I-girentuximab PET/CT for diagnosing clear cell renal cell carcinoma and Tc-sestamibi SPECT/CT for diagnosing renal oncocytomas and hybrid oncocytic/chromophobe tumors.
Molecular imaging offers a noninvasive means of determining the histology of renal tumors thereby aiding in the risk stratification of patients presenting with a renal mass. Future work aims to develop a molecular imaging test that employs dual radiotracers allowing for the more precise characterization of renal tumors in a convenient single radiologic study.
探讨分子成像在肾肿块特征描述中的作用。
偶然发现的肾肿块根据其潜在组织学表现出不同的恶性潜能。出现肾肿块的患者应进行个体风险分层，包括对其肿瘤组织学进行特征描述。目前，解剖成像技术无法可靠地区分各种肾肿瘤亚型。尽管肾肿块活检在这方面有帮助，但该操作存在局限性。分子成像提供了一种确定肾肿瘤组织学的非侵入性方法。已显示在此应用中具有特别前景的成像检查包括用于诊断透明细胞肾细胞癌的I-吉妥昔单抗PET/CT以及用于诊断肾嗜酸细胞瘤和嗜酸细胞/嫌色细胞混合性肿瘤的锝- sestamibi SPECT/CT。
分子成像提供了一种确定肾肿瘤组织学的非侵入性方法，从而有助于对出现肾肿块的患者进行风险分层。未来的工作旨在开发一种分子成像检查，该检查采用双示踪剂，以便在一次便捷的放射学研究中更精确地描述肾肿瘤特征。
